TW202402808A - 抗-b7h3抗體及其用途 - Google Patents

抗-b7h3抗體及其用途 Download PDF

Info

Publication number
TW202402808A
TW202402808A TW112118340A TW112118340A TW202402808A TW 202402808 A TW202402808 A TW 202402808A TW 112118340 A TW112118340 A TW 112118340A TW 112118340 A TW112118340 A TW 112118340A TW 202402808 A TW202402808 A TW 202402808A
Authority
TW
Taiwan
Prior art keywords
antibody
antigen
amino acid
binding portion
cancer
Prior art date
Application number
TW112118340A
Other languages
English (en)
Chinese (zh)
Inventor
榮乃燕
卓智 王
李婕
繼杰 顧
Original Assignee
中國大陸商上海藥明生物技術有限公司
愛爾蘭商藥明生物技術愛爾蘭有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 中國大陸商上海藥明生物技術有限公司, 愛爾蘭商藥明生物技術愛爾蘭有限公司 filed Critical 中國大陸商上海藥明生物技術有限公司
Publication of TW202402808A publication Critical patent/TW202402808A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW112118340A 2022-05-18 2023-05-17 抗-b7h3抗體及其用途 TW202402808A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
WOPCT/CN2022/093524 2022-05-18
CN2022093524 2022-05-18

Publications (1)

Publication Number Publication Date
TW202402808A true TW202402808A (zh) 2024-01-16

Family

ID=88834684

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112118340A TW202402808A (zh) 2022-05-18 2023-05-17 抗-b7h3抗體及其用途

Country Status (12)

Country Link
US (1) US20250313633A1 (enExample)
EP (1) EP4526346A1 (enExample)
JP (1) JP2025517737A (enExample)
KR (1) KR20250011957A (enExample)
CN (1) CN119256010A (enExample)
AU (1) AU2023273853A1 (enExample)
CA (1) CA3253563A1 (enExample)
CL (1) CL2024003486A1 (enExample)
IL (1) IL316510A (enExample)
MX (1) MX2024014232A (enExample)
TW (1) TW202402808A (enExample)
WO (1) WO2023222017A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118829656B (zh) * 2023-12-01 2026-04-24 苏州智核生物医药科技有限公司 B7h3结合多肽及其用途
WO2025157244A1 (zh) * 2024-01-25 2025-07-31 山东先声生物制药有限公司 抗b7h3抗体及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12012501751A1 (en) * 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
AU2015306621B2 (en) * 2014-08-27 2021-05-06 Memorial Sloan Kettering Cancer Center Antibodies, compositions, and uses
UA125593C2 (uk) * 2017-03-31 2022-04-27 Джянгсу Хенгруй Медісін Ко., Лтд. Антитіло в7-н3, його антигензв'язуючий фрагмент та його медичне застосування
KR102732027B1 (ko) * 2019-07-09 2024-11-20 주식회사 와이바이오로직스 B7-h3(cd276)에 특이적으로 결합하는 항체 및 그의 용도
CN112851812B (zh) * 2020-06-30 2021-09-14 广州百暨基因科技有限公司 抗b7h3抗体及其应用
CN113402610B (zh) * 2021-06-09 2023-02-24 英诺湖医药(杭州)有限公司 一组b7h3单克隆抗体及其医药用途
CN113336851B (zh) * 2021-06-30 2021-12-24 徐州医科大学 新型全人源抗人b7h3抗体、包含所述抗体的组合物及其应用

Also Published As

Publication number Publication date
CA3253563A1 (en) 2023-11-23
CL2024003486A1 (es) 2025-06-13
WO2023222017A1 (en) 2023-11-23
US20250313633A1 (en) 2025-10-09
CN119256010A (zh) 2025-01-03
JP2025517737A (ja) 2025-06-10
MX2024014232A (es) 2025-03-07
AU2023273853A1 (en) 2024-10-24
EP4526346A1 (en) 2025-03-26
KR20250011957A (ko) 2025-01-22
IL316510A (en) 2024-12-01

Similar Documents

Publication Publication Date Title
EP3872093A1 (en) Anti-cldn128.2 antibody and uses thereof
JP2024029261A (ja) 新規の抗ｐｄ－１抗体
TWI813934B (zh) 一種雙特異性抗pd-l1/vegf抗體及其用途
JP2023511898A (ja) 二重特異性抗ｐｄ－ｌ１／ｖｅｇｆ抗体及びその使用
US20250277054A1 (en) Psma antibodies and uses thereof
CN110540593B (zh) 新型的抗cd3/抗cd20双特异性抗体
US20250313633A1 (en) Anti-B7H3 antibody and Uses thereof
CN112552411B (zh) 新型抗pd-l1/抗lag-3双特异性抗体及其用途
JP7430137B2 (ja) 抗体および使用方法
US20250026833A1 (en) A bispecific anti-pd-l1/vegf antibody and uses thereof
TW202144397A (zh) 一種雙功能融合蛋白及其用途
US20240376194A1 (en) D3-binding molecules and uses thereof
JP2024500093A (ja) Ｐ－カドヘリンに対する抗体及びその使用
TWI908113B (zh) 抗tigit抗體及其用途
WO2026037400A1 (en) Anti-msln antibodies and uses thereof
HK40117348A (zh) 抗b7h3抗体及其用途
TWI847270B (zh) D3結合分子及其用途
WO2024251161A1 (en) Anti-tigit x pvrig antibodies and uses thereof
US12630626B2 (en) Anti-CLDN18.2 antibody and uses thereof
KR20240162568A (ko) 항-her2/항-cd47 분자 및 이의 용도